Phaseline

Companies › Ascension Health

Ascension Health: clinical trials, targets and expected readouts

1 active drug program in 51 registered trials: 19 Phase 4, 17 Phase 3, 12 Phase 2, 3 Phase 1; Neurology, Cardiovascular, Gastroenterology, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tranexamic acid
Plasminogen inhibitor
PLGPhase 2Postoperative Blood Loss; Knee Osteoarthritis; Hemorrhage; Melasma …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05047133Tranexamic acidPhase 2Postoperative Blood LossOtherJul 2022
NCT05099276Tranexamic acidPhase 4Knee OsteoarthritisImmunologyDec 2023
NCT07098780Tranexamic acidPhase 4HemorrhageMetabolic and endocrineJul 2025
NCT07034560Tranexamic acidPhase 4MelasmaImmunologyNov 2025
NCT06881628Tranexamic acidPhase 4Upper Gastrointestinal Bleeding (UGIB)GastroenterologyDec 2025
NCT06997796Tranexamic acidPhase 1Epistaxis NosebleedOtherDec 2025
NCT07263841Tranexamic acidPhase 2Post Burn Facial HyperpigmentationImmunologyDec 2025
NCT07263841Tranexamic acidPhase 2Post Burn Facial HyperpigmentationImmunologyDec 2025
NCT04233749Tranexamic acidPhase 2Lichen Planus PigmentosusImmunologyDec 2025
NCT06023212Tranexamic acidPhase 1Metastasis Spinal TumorOncologyJan 2026
NCT05470816Tranexamic acidPhase 3Surgical Site InfectionInfectious diseaseAug 2026
NCT05345613Tranexamic acidPhase 4Colon NeoplasmOncologySep 2026
NCT07460518Tranexamic acidPhase 4Benign Prostatic HyperplasiaGenitourinaryOct 2026
NCT05836831Tranexamic acidPhase 4Intracerebral Hemorrhagic StrokeNeurologyNov 2026
NCT06665594Tranexamic acidPhase 2Facial Filler InjectionsOtherNov 2026
NCT06109155Tranexamic acidPhase 4Surgery, CardiacCardiovascularDec 2026
NCT06128330Tranexamic acidPhase 4Antifibrinolytic AgentsOtherDec 2026
NCT04521881Tranexamic acidPhase 3Traumatic Brain InjuryNeurologyDec 2026
NCT04910464Tranexamic acidPhase 3SepsisInfectious diseaseJan 2027
NCT03552705Tranexamic acidPhase 2Anterior Cruciate Ligament ReconstructionOtherJan 2027
NCT06450392Tranexamic acidPhase 4Orbital EdemaOphthalmologyJan 2027
NCT06754371Tranexamic acidPhase 4Postpartum HemorrhageImmunologyJan 2027
NCT06229483Tranexamic acidPhase 3Brain TumorOncologyJan 2027
NCT04448184Tranexamic acidPhase 3Hematologic NeoplasmsOncologyFeb 2027
NCT06337838Tranexamic acidPhase 3Chronic Kidney DiseasesGenitourinaryFeb 2027
NCT03553186Tranexamic acidPhase 3Spinal DeformityOtherMar 2027
NCT05713630Tranexamic acidPhase 3Subdural HematomaOtherMar 2027
NCT07869537Tranexamic acidPhase 4Trauma CoagulopathyHematologyMar 2027
NCT06599762Tranexamic acidPhase 2Myelodysplastic SyndromesOncologyApr 2027
NCT06820177Tranexamic acidPhase 4AbortionOtherMay 2027
NCT06832878Tranexamic acidPhase 4ArthroplastyOtherJun 2027
NCT04304625Tranexamic acidPhase 3Postpartum HemorrhageOtherJun 2027
NCT03063892Tranexamic acidPhase 4Hip FracturesOtherJul 2027
NCT02314988Tranexamic acidPhase 2Spinal InjuriesOtherJul 2027
NCT05053867Tranexamic acidPhase 3Pulmonary HemorrhageOncologyJul 2027
NCT02261415Tranexamic acidPhase 3CancerOncologyAug 2027
NCT06057675Tranexamic acidPhase 2Postoperative BleedingOncologyAug 2027
NCT06657924Tranexamic acidPhase 2BleedingGastroenterologySep 2027
NCT05562609Tranexamic acidPhase 3Postpartum HemorrhageOtherSep 2027
NCT05370820Tranexamic acidPhase 2Post Partum HemorrhageOtherOct 2027
NCT07893067Tranexamic acidPhase 4Melasma (Facial Melasma)ImmunologyOct 2027
NCT06736860Tranexamic acidPhase 4Trauma CoagulopathyHematologyOct 2027
NCT06379724Tranexamic acidPhase 4BurnsOtherDec 2027
NCT06070350Tranexamic acidPhase 3Hemorrhagic ShockOtherJun 2028
NCT06902714Tranexamic acidPhase 3Shoulder ArthroplastyImmunologyJul 2028
NCT06519422Tranexamic acidPhase 3AnaemiaHematologyAug 2028
NCT05899465Tranexamic acidPhase 3MelanomaOncologySep 2028
NCT07245264Tranexamic acidPhase 2Chronic Subdural HematomaCardiovascularNov 2028
NCT06270407Tranexamic acidPhase 4Surgical ComplicationOtherDec 2028
NCT05774717Tranexamic acidPhase 1SurgeryOtherApr 2029
NCT03582293Tranexamic acidPhase 3Hematoma, Subdural, ChronicCardiovascularApr 2029

Targets

PLG (1)

Companies with the same targets

Jiangsu Jingze Biopharmaceutical Supergene Youssef Yammine

Companies built like this

Jiangsu Jingze Biopharmaceutical Novaliq Guangzhou Novaken Pharm Acacia Pharma Laboratorio Elea Phoenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.